UPDATED FEB 2013 ELTP Due Diligence Investor Info

New Post Public Reply Private Reply Replies (0) Message Board

Feb 5, 2013 at 9:37 AM

UPDATED FEB 2013 ELTP Due Diligence Investor Info

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Elite has five commercial products with five additional products under review, pending approval by the FDA.

Elite’s lead pipeline products include abuse resistant opioids utilizing the Company’s patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse.

Elite also has partnered with Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories.

Elite operates a FDA GMP(Good Manufacturing Practices) and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.

Link to 11 Billion dollar NYSE company - ACT- Actavis Labs distributing ELTP’s Phendimetrazine

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=84198

Link to product pipeline:

http://www.elitepharma.com/product_pipeline.asp

Link to SEC filings:

http://investing.money.msn.com/investments/se...ymbol=ELTP

Recent PR's:

http://www.elitepharma.com/investor_relations.asp

12/13/2012 ELITE PHARMACEUTICALS, INC. ANNOUNCES AGREEMENT FOR SUPPLY OF PHENTERMINE ACTIVE INGREDIENT

11/14/2012 Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal 2013
...Revenues from new products continue to grow

PATENTS:

Since our incorporation, we have secured eight United States patents of which two have been assigned for a fee to Celgene Corporation for pulsed delivery of methylphenidate. Elite’s patents are:
PATENTS
U.S. patent 5,871,776
U.S. patent 5,902,632
U.S. patent 5,837,284 (assigned to Celgene Corporation)
U.S. patent 6,620,439
U.S. patent 6,635,284 (assigned to Celgene Corporation)
U.S. patent 6,926,909
U.S. patent 6,984,402
U.S. patent 8,182,836
We also have pending applications for four additional U.S. patents and four foreign patents. The pending patent applications are for an opioid agonist and antagonist products that Elite is developing to be used with controlled-release Oxycodone and other opioids to minimize the abuse potential for the opioids.

CEO Funding

Ceo Jerry Treppel personally invested 1 million dollars of his own money in 2 $500,000 non-dilutive financings to keep the research and products sales increases on target.

Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) announced today that it has amended the bridge loan agreement ("Loan Agreement") with Jerry Treppel, Elite's Chairman & CEO. Pursuant to the amendment to the Loan Agreement, Mr. Treppel has agreed to increase the maximum principal amount of the line of credit from $500,000 to $1,000,000. All other terms remain the same. The additional proceeds will be used primarily for working capital to support Elite's increase in production and growth of sales.
A copy of the amendment to the Loan Agreement will be filed in a Current Report on Form 8-K which will be filed with the Securities and Exchange Commission.

http://ih.advfn.com/p.php?pid=nmona&article=55384279

Outstanding shares :

As of November 8, 2012 the issuer had outstanding 350,337,260 shares of common stock

Transfer Agent:

American Stock Transfer & Trust Company, LLC.
6201 15th Avenue
Brooklyn, NY 11219

Phone: 800-937-5449
Fax: 718-236-2641
E Mail: info@amstock.com

Investor Relations Contact:

Dianne Will
(201) 367-7889
E Mail: dianne@elitepharma.com

http://www.elitepharma.com/ir_contact_us.asp

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Invasive Procedures Don't Extend Life in Stable Heart Disease

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Quantum Space Joins $185M NASA Lunar Transport Deal

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

TCL's Display Future: AI Meets Screens at DTC 2026

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Aurora Innovation Faces Legal Heat Amid Delays

Production Snags at Aurora Innovation Ah, investing – not for the faint-hearted. One day you're riding high, the next you're scraping by, and Aurora Innovation's (NASDAQ:AUR) investors just hit a rough patch. The autonomous trucking darling announced unexpected delays in its delivery schedule, sending shockwaves through its stock price and shaking investor confidence....

Johnson & Johnson Unveils Promising PsA Treatment Data

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Evaluating GLP-1 Telehealth? Key Questions to Consider

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Off-Broadway Play 'DUST' Raises Autism Support Funds

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...

ecozy's Brezzano Switch: Brewing Simplicity at Home

Breathe the aroma, sip the innovation. ecozy just threw their Brezzano Switch into the arena, and here's the deal: it's a no-nonsense, get-your-caffeine-fix kind of machine aimed at making your mornings simple without compromising on flavor. Unique Features of the Brezzano Switch So, what's cooking? Get this—it's not just any coffee contraption. Built sleek and compact,...

Adding Fireplaces: Home Comfort or Construction Headache?

Sizing Up the Installation Options Slapping a fireplace into a home sounds more like a pipe dream than a practical project for most folks. But according to fireplace whiz Jimmy Smith down in North Charleston, the times are a-changin'. These days, with advances in technology, homeowners can actually pull it off without collapsing their living room walls. Nitty-Gritty:...